Does SOLV pay a dividend and is it safe?

Solventum Corporation (SOLV) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / SOLV / dividends

GKOS (57) PEN (57) BAX (50) GMED (69) ⌘ Pro Terminal →

Solventum Corporation (SOLV) Dividend Safety Gauge & 10-Year DRIP Compounder

$84.75 +4.21% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $85.23

Solventum Corporation (SOLV) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID rating (44/100 RQD Confidence). Alongside weak composite pillar scores, our SEC filing scanner spotted paper earnings outpacing operating cash flow (+288.9% (NI vs OCF)).

ROARABLE D • SELL / AVOID Cap $13.84B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SOLV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SOLV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Solventum Corporation (NYSE: SOLV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $84.75 (+4.21% 1D, market cap $13.84B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 10/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SOLV compare to GKOS and PEN in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SOLV carries a Roarable D (44/100 RQD), trailing P/E of 9.1x, gross margin of 53.5%, and ROIC of 18.7%. By comparison, GKOS (Glaukos Corporation) holds a D+ grade (57/100 RQD, P/E N/A, ROIC -13.7%, cap $14.07B) and PEN (Penumbra Inc.) posts a D+ grade (57/100 RQD, P/E 71.4x, ROIC 10.6%, cap $12.57B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while SOLV leads on capital efficiency (18.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SOLV?

▼

Per SOLV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001964738), Solventum Corporation generated $8.32B in revenue (+0.9% YoY), $1.56B in net income, and -$10.0M in free cash flow against $14.29B in total assets and $5.04B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $85.23 (+0.57%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SOLV)Realized 20D OHLCV Swing Band: ±5.6%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY SOLV SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+10/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 50% Net Buy • Disciplined Float (+0.52% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+9/20 pts (20% of score)

Altman Z-Score 2.25 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$87.26-0.7% Next Q

Q2 (-2Q)

Grade D$86.67-5.6% Next Q

Q3 (-1Q)

Grade D$81.85+3.5% Next Q

Current

Grade D$84.75-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SOLV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SOLV currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($87.62) and Max Pain ($88.99) forces dealer call-delta covering toward $98.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SOLV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SOLV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SOLV)

✓Walkthrough of SOLV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SOLV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.67%📐 HORIZONTAL RANGE

2026-11-03O $83.56H $84.75L $81.33C $84.75VOL 1.07M

RES: $102.2SUP: $80.74SMA50: $87.62SMA200: $78.42

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SOLV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SOLV Butterfly Map → + Track SOLV →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

-3.0%/yr Implied 5Y Growth

vs. +0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SOLV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SOLV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SOLV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SOLV)

Health Care Rank #379 of 1016 ⚔️ GKOS vs SOLV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SOLV vs. GKOS, PEN, BAX, GMED)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Solventum Corporation (SOLV) ranks #379 by composite RQD confidence (44/100, grade D) and #85 by equity capitalization ($13.84B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while SOLV leads on capital efficiency and profitability with 18.7% ROIC and 53.5% gross margin. GMED currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with SOLV at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SOLV ACTIVE Solventum Corporation	D	44/100	9.1x	53.5%	18.7%	+4.21%	$13.84B	Benchmark Subject
GKOS Glaukos Corporation	D+	57/100	—	55.7%	-13.7%	+0.43%	$14.07B	/gkos-vs-solv →
PEN Penumbra Inc.	D+	57/100	71.4x	67.1%	10.6%	+0.75%	$12.57B	/pen-vs-solv →
BAX Baxter International Inc.	D	50/100	—	30.1%	-2.4%	+5.30%	$11.90B	/bax-vs-solv →
GMED Globus Medical Inc.	C+	69/100	20.7x	67.4%	8.7%	+1.81%	$10.48B	/gmed-vs-solv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001964738

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Solventum Corporation (SOLV) reported GAAP revenue of $8.32B (+0.9% vs. FY2024 revenue of $8.25B , and +1.6% cumulative change since FY2023) , GAAP net income of $1.56B, operating cash flow of $369.0M, and free cash flow of -$10.0M (-101.2% YoY). On the balance sheet, SOLV closed FY2025 with $14.29B in total assets against $5.04B in total debt (Altman Z-Score: 2.25, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$8.32B	$1.56B	$369.0M	-$10.0M	$14.29B	$5.04B
FY2024 (FY)	2024-12-31	$8.25B	$479.0M	$1.19B	$805.0M	$14.46B	$7.81B
FY2023 (FY)	2023-12-31	$8.20B	$1.35B	$1.92B	$1.55B	$9.84B	$2.30B

3. SOLV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SOLV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SOLV compare to GKOS and PEN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SOLV?

Where is SOLV trading relative to its 50-day, 200-day, and 52-week technical levels?

SOLV last traded at $84.75 (+4.21% on volume of 1,243,035 shares), positioning the stock -3.28% below its 50-day simple moving average ($87.62) and +8.07% above its 200-day simple moving average ($78.42). Across its 52-week range of $62.38 to $94.16, SOLV sits at the 70.4% percentile with a 14-day RSI of 37.9 (NEUTRAL RANGE) and an implied next-earnings move of ±5.6% ($80.00 to $89.50).

Direct Sub-Reports: SOLV RQD Cockpit SOLV 12M Forecast SOLV Earnings & Move SOLV Dividends & DRIP SOLV Insiders & 13F SOLV Whale Options SOLV Profit Sankey SOLV News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

SOLV — Solventum Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Solventum Corporation (SOLV) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $84.75 (+4.21% 1D, market capitalization $13.84B).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of 18.7%, gross margin of 53.5%, operating margin of 26.2%, and free cash flow yield of -0.07%.
Whale 13F & Options Flow (8/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.06x equity beta, Altman Z-Score of 2.25, Piotroski F-Score of 6/9, and Debt/Equity of 1.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Solventum Corporation (SOLV) is a NYSE-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry..2B. — for detailed product lines, customer segments, or revenue mechanics beyond the sector and industry classification and reported financial figures.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Solventum Corporation (SOLV) reported $8.32B in annual revenue (up from $8.25B in FY2024, +0.9% YoY) and $1.56B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.20B revenue, $1.35B net income) through FY2025, SOLV scaled operating cash flow to $369.0M and free cash flow to -$10.0M, backed by $14.29B in total assets against $5.04B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.07% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $62.38 – $94.16 52-week range.
🐻 Primary Bear Case & Valuation Risk: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Investors must weigh 9.1x trailing P/E and 7.3x EV/EBITDA against 26.2% operating margins and a 1.06x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The principal 2nd-order watch item is the accrual gap: if receivables and working-capital builds do not reverse, the earnings-to-cash divergence could persist into the next reporting cycle and pressure the forensic and cash-engine pillars further.

Key Question #1: Can SOLV sustain or expand its 26.2% operating margin and 18.7% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $8.32B and free cash flow of -$10.0M, how will capital allocation balance growth reinvestment against $5.04B in total debt?
Key Question #3: How sensitive is SOLV's 8.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.06x)?

SOLV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Solventum Corporation (SOLV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SOLV Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Solventum Corporation (SOLV) Stock Forecasts

Yahoo Finance report covering Solventum Corporation (SOLV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Solventum (SOLV) Stock Price, News & Analysis $SOLV

MarketBeat report covering Solventum Corporation (SOLV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

At 4:30 p.m. Eastern on Nov. 5, Solventum will discuss its quarterly results.

Stock Titan report covering Solventum Corporation (SOLV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

FDA clears two wound treatments for combined use, which may allow fewer dressing changes.

Stock Titan report covering Solventum Corporation (SOLV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Solventum’s Quarterly Earnings Preview: What You Need to Know

Yahoo Finance report covering Solventum Corporation (SOLV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

(SOLV) Volatility Zones as Tactical Triggers

Stock Traders Daily report covering Solventum Corporation (SOLV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

2 cash-burning stocks for long-term investors and 1 we turn down

Yahoo Finance report covering Solventum Corporation (SOLV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.dars.gov.et • 1d ago

SOLV Q2 2026 Earnings: EPS Tops Estimates by 31% Despite Stock Slide - Earnings Outlook Update

www.dars.gov.et report covering Solventum Corporation (SOLV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SOLV Bull vs. Bear Conversation Board — What's Your Call at $84.75?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SOLV 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $102.48 (+26.0%)

📌 Pinned Debate

SOLV trades at a P/E (TTM) of 9.1 and Forward P/E of 8.5 with ROIC of 18.7%, a valuation discount on reported earnings.

Long SOLV at $81.33 targeting $102.48. SOLV trades at a P/E (TTM) of 9.1 and Forward P/E of 8.5 with ROIC of 18.7%, a valuation discount on reported earnings.. Institutional whale score is 8/20 and the risk/reward vs. the $62.38 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 8/20 institutional whale-flow stock at $81.33 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $64.25 (-21.0%)

Spot @ $81.33

Net Income grew +220.0% while Operating Cash Flow fell -68.9%, flagged as a BEARISH accounting mirage with severity 87 and FCF yield of

Fading this rally in SOLV at $81.33. Net Income grew +220.0% while Operating Cash Flow fell -68.9%, flagged as a BEARISH accounting mirage with severity 87 and FCF yield of -0.07%.. With a beta of 1.06 and the stock sitting at $81.33 (52-wk range $62.38–$94.16), the easy multiple expansion is already priced in.